title: [Inhibition of the stellate cells using lisinopril and lovastatin for prophylaxis of pancreatic stump fibrosis after performance of distal resection in a model of chronic alcoholic pancreatitis].
abstract: Complex application of lisinopril (inhibitor of angiotensin-converting enzyme) and lovastatin (inhibitor of HMG-CoA reductase) inhibits pancreatic fibrosis in the rats, having alcoholic chronic pancreatitis after distal pancreatic resection (DPR). Lisinopril and lovastatin were injected to the rats after DPR in dose 10 mg/kg during 3 weeks. Immunohistochemical markets, such as alpha-smooth-muscle actin (alpha-SMA), desmin, glial fibrillary acidic protein (GFAP), vimentin, and expression of matrix metalloproteinase-1 (MMP-1) as well as inhibitor of matrix metalloproteinase-2 (TIMP-2) were detected for estimation of therapeutic impact on activity and quantity of stellate pancreatic cells. Under the influence of lisinopril and lovastatin there were observed lowering in the stellate pancreatic cells activity and in expression of SMA, desmin, GFAP, vimentin and TIMP-2, the MMP-1 and TIMP-2 ratio have had increased significantly and severity of fibrotic pancreatic affection had reduced trustworthy in comparison w such, occurring in a control group.
authors.forename: M E
authors.initials: ME
authors.lastname: Nichitaĭlo
authors.forename: D A
authors.initials: DA
authors.lastname: Kravchenko
authors.forename: I S
authors.initials: IS
authors.lastname: Shpon'ka
authors.forename: E B
authors.initials: EB
authors.lastname: Medvetskiĭ
authors.forename: I M
authors.initials: IM
authors.lastname: Savitskaia
authors.forename: I I
authors.initials: II
authors.lastname: Bulik
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Khil'ko
mesh_terms: D000199:Actins / Q000235:genetics / Q000378:metabolism; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D003893:Desmin / Q000235:genetics / Q000378:metabolism; D005260:Female; D005355:Fibrosis / Q000517:prevention & control; D015870:Gene Expression / Q000187:drug effects; D005904:Glial Fibrillary Acidic Protein / Q000235:genetics / Q000378:metabolism; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D017706:Lisinopril / Q000494:pharmacology*; D008148:Lovastatin / Q000494:pharmacology*; D020781:Matrix Metalloproteinase 1; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D010180:Pancreatectomy; D058954:Pancreatic Stellate Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D019512:Pancreatitis, Alcoholic / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000235:genetics / Q000378:metabolism; D014746:Vimentin / Q000235:genetics / Q000378:metabolism
chemical_list: D000199:Actins; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D003893:Desmin; D005904:Glial Fibrillary Acidic Protein; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017706:Lisinopril; D008148:Lovastatin; D020781:Matrix Metalloproteinase 1; D019716:Tissue Inhibitor of Metalloproteinase-2; D014746:Vimentin; C498862:Acta2 protein, rat